Utilizing New Prescription Drugs: Disparities among Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanic Whites

University of Maryland, Baltimore, Baltimore, Maryland, United States
Health Services Research (Impact Factor: 2.78). 08/2007; 42(4):1499-519. DOI: 10.1111/j.1475-6773.2006.00682.x
Source: PubMed


To examine racial and ethnic disparities in new prescription drug use.
Secondary data analyses of the Medical Expenditure Panel Survey (1996-2001), a national survey representative of U.S. noninstitutionalized civilian population. Drug approval dates were from the GenRx database of Mosby.
A negative binomial model was used to compare annual number of times when new drugs were obtained across racial and ethnic groups. Covariates in the model were demographic, economic characteristics, and health status. Drugs were considered new if approved within the past 5 years. We compared non-Hispanic whites with non-Hispanic blacks, and non-Hispanic whites with Hispanic whites, respectively, to examine racial and ethnic disparities separately.
Descriptive analyses found smaller racial disparities than ethnic disparities: the average annual number of times when new drugs were obtained was higher among non-Hispanic whites than non-Hispanic blacks (1.71 versus 1.36; p<.01) and Hispanic whites (1.71 versus 1.11; p<.01). Multivariate analyses found smaller ethnic than racial disparities: the number was 22-33 percent lower among non-Hispanic blacks than non-Hispanic whites (significant), and 5-16 percent lower among Hispanic whites than non-Hispanic whites (not always significant), respectively. While the absolute racial disparities decreased over the early years of the life cycles of the products, the reduction in disparities over time was not significant.
There are racial disparities in the use of new medications, which persist during the first 5 years of marketing. Socioeconomic and health characteristics account for a larger share of ethnic disparities than racial disparities.

Download full-text


Available from: Fadia T Shaya,
  • Source
    • "Still, several pieces of evidence are consistent with the prediction that innovations have led to disparities in pharmaceutical use. Lleras-Muney and Lichtenberg (2002) and Wang et al. (2007) use the age of a drug, defined as the number of years since approval by the Food and Drug Administration (FDA), to measure innovation. In data from the Medical Expenditure Panel "

    Advances in health economics and health services research 02/2008; 19:71-94. DOI:10.1016/S0731-2199(08)19004-5
  • Source

  • [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies reported that some minority childhood cancer patients are likely to develop worse outcomes than white children. This study examines whether there are racial and ethnic disparities in health expenditures among children with cancer. Research design and methods: A retrospective study was conducted among children (younger than 20) with cancer diagnoses in the Medical Expenditure Panel Survey (MEPS; 1996 to 2004). Total health expenditures and the following subcategories were examined across racial and ethnic groups: (1) office-based visits; (2) outpatient visits; (3) inpatient and emergency room visits; (4) home health care; (5) prescription drugs; and (6) dental, vision, and other health care expenditures. Consumer price indexes were used to convert all expenditures to 2004 dollars. A classical linear model was analyzed using the natural logarithm of health expenditures as the dependent variable, with the purpose of determining whether there were racial and ethnic differences in health expenditures after adjusting for confounding factors. Study sample included 394 non-Hispanic whites (weighted to 4 958 685), 53 non-Hispanic blacks (weighted to 352 534), and 94 Hispanic whites (weighted to 424 319). Hispanic blacks and other minority populations were excluded from the analysis due to insufficient sample size. The annual total health expenditure for treating each child with cancer was $3467.40, $2156.15, and $5545.34, respectively, among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. The differences in the various subcategories of health expenditures across racial and ethnic groups were generally not significant according to both descriptive and analytical analyses with very few exceptions. This study did not identify significant racial and ethnic disparities in health care costs. However, one important study limitation is the small sample size of the minority populations in the study sample.
    Current Medical Research and Opinion 04/2008; 24(3):847-58. DOI:10.1185/030079908X273390 · 2.65 Impact Factor
Show more